Splenectomy for HIV-Related Immune Thrombocytopenia

Splenectomy for immune thrombocytopenia.

As with most reports of splenectomy for immune thrombocytopenia, the recent study claiming efficacy of splenectomy for human immunodeficiency virus (HIV)-related thrombocytopenia is uncontrolled, and combines responses of more and less severely thrombocytopenic patients.' In addition, important information is omitted. What were the mean platelet count increases, partial versus complete response...

HIV related immune thrombocytopenia.

Role of Laparoscopic Splenectomy in Elderly Immune Thrombocytopenia

The management of older patients with chronic primary immune thrombocytopenia (ITP) is still very challenging because of the fragility of older patients who frequently have severe comorbidities and/or disabilities. Corticosteroid-based first-line therapies fail in most of the cases and patients require a second-line treatment, choosing between rituximab, thrombopoietin-receptor agonists and spl...

Long-term complications of splenectomy in adult immune thrombocytopenia

The recent large decrease in splenectomy use for chronic immune thrombocytopenia (ITP) is partly due to still-unsolved questions about long-term safety. We performed the first single-center exposed/unexposed cohort study evaluating the long-term incidence of splenectomy complications in patients with primary ITP. Overall, 83 patients who underwent splenectomy more than 10 years ago (exposed) we...

Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia.

Sixty-eight patients, followed in a prospective cohort study of 185 human immunodeficiency virus (HIV)-infected patients with severe immune thrombocytopenia (platelets < 50 x 10(9)/L), underwent splenectomy, 2 to 41 months (median: 10 months) after immune thrombocytopenic purpura (ITP) was diagnosed. The mean platelet count increased from 18 x 10(9)/L to 223 x 10(9)/L with a persistent increase...